Autoantibodies against type I interferons in COVID-19 infection: A systematic review and meta-analysis

Abstract

Objectives: In this study, we aimed to study the rate of autoantibodies against type I interferons (IFNs) in patients with COVID-19 and analyze its dependence on severity of infection and some other variables. Methods: A systemic review with the search terms: “COVID-19” or “SARS-CoV-2” and “autoantibodies” or “autoantibody” and “IFN” or “interferon” for the period 20 December 2019 to 15 August 2022 was carried out using PubMed, Embase, Cochrane, and Web of Science. R 4.2.1 software was used for meta-analysis of the published results. Pooled risk ratios and 95% confidence intervals (CIs) were calculated. Results: We identified eight studies involving 7729 patients, of whom 5097 (66%) had severe COVID-19 and 2632 (34%) had mild or moderate symptoms. The positive rate of anti-type-I-IFN-autoantibodies in the total dataset was 5% (95% CI, 3-8%), but reached 10% (95% CI, 7-14%) in those with severe infection. The most common subtypes were anti-IFN-α (89%) and anti-IFN-ω (77%). The overall prevalence in male patients was 5% (95% CI, 4-6%), and in female patients 2% (95% CI, 1-3%). Conclusion: Severe COVID-19 is associated with high rates of autoantibodies against type-I-IFN and more so in male than female patients.

Keywords

• COVID-19
• Anti-type-I-IFN-autoantibodies
• Meta-analysis